Molecular Partners to Showcase Three Cancer Therapies at AACR 2026 — Molecular Partners AG

Event summary

Molecular Partners will present three posters at AACR 2026, showcasing advancements in DARPin therapeutics for cancer treatment.
Presentations include a logic-gated Switch-DARPin T cell engager for ovarian cancer, a computational workflow for cancer immunotherapies, and a Radio-DARPin candidate for small cell lung cancer.
The event takes place April 17-22, 2026, in San Diego, California.
Molecular Partners highlights its proprietary Radio-DARPin and Switch-DARPin platforms to address limitations in targeted radiopharmaceuticals and immune cell engagers.

The big picture

Molecular Partners' presentations at AACR 2026 underscore its focus on innovative cancer therapies, particularly in targeted radiopharmaceuticals and immune cell engagers. The company's proprietary platforms aim to address key limitations in existing treatments, positioning it as a notable player in the biotech sector. The strategic emphasis on computational workflows and data-driven approaches reflects broader industry trends toward precision medicine and personalized cancer treatments.

What we're watching

Clinical Validation: How the data from these presentations will impact the clinical validation of Molecular Partners' DARPin therapeutics.
Market Differentiation: Whether Molecular Partners can sustain its competitive edge with its proprietary platforms in the crowded cancer immunotherapy space.
Partnership Dynamics: The pace at which Molecular Partners can leverage its collaborations, such as with Orano Med, to accelerate development timelines.